Innovent Biologics, Inc., a biopharmaceutical company that develops, manufactures and commercializes treatments for cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Co., expanded their strategic commercialization partnership in China. Under the agreement, Innovent obtains the sole commercialization rights to import, market, promote, distribute Cyramza (ramucirumab) and Retsevmo (selpercatinib) once approved in China, and Innovent has the right of first negotiation for...